Yves Albert DeClerck

List of Publications by Year
in descending order

87 papers	7,659 citations	50170 46 h-index	53109 85 g-index
95 all docs	95 docs citations	95 times ranked	10818 citing authors

#	Article	IF	Citations
1	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	13.5	691
2	Interleukin-6 in bone metastasis and cancer progression. European Journal of Cancer, 2010, 46, 1223-1231.	1.3	321
3	Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer and Metastasis Reviews, 2010, 29, 249-261.	2.7	304
4	VÎ±24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. Journal of Clinical Investigation, 2009, 119, 1524-1536.	3.9	287
5	Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP). Journal of Biological Chemistry, 1998, 273, 1216-1222.	1.6	258
6	Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials. Cancer Research, 2013, 73, 4965-4977.	0.4	231
7	Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment. Cancer Research, 2004, 64, 1675-1686.	0.4	203
8	Proteases, Extracellular Matrix, and Cancer. American Journal of Pathology, 2004, 164, 1131-1139.	1.9	202
9	Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer and Metastasis Reviews, 2006, 25, 35-43.	2.7	195
10	Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells. Cancer Research, 2009, 69, 329-337.	0.4	164
11	Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10026-10031.	3.3	161
12	TGF-Î²3-induced Palatogenesis Requires Matrix Metalloproteinases. Molecular Biology of the Cell, 2001, 12, 1457-1466.	0.9	151
13	The Contribution of Bone Marrowâ€“Derived Cells to the Tumor Vasculature in Neuroblastoma Is Matrix Metalloproteinase-9 Dependent. Cancer Research, 2005, 65, 3200-3208.	0.4	146
14	Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Research, 2015, 75, 2969-2974.	0.4	142
15	Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis. Cancer Cell, 2008, 14, 324-334.	7.7	132
16	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Research, 2017, 77, 5142-5157.	0.4	130
17	Differential Inhibition of Membrane Type 3 (MT3)-Matrix Metalloproteinase (MMP) and MT1-MMP by Tissue Inhibitor of Metalloproteinase (TIMP)-2 and TIMP-3 Regulates Pro-MMP-2 Activation. Journal of Biological Chemistry, 2004, 279, 8592-8601.	1.6	126
18	Mechanisms of pericyte recruitment in tumour angiogenesis: A new role for metalloproteinases. European Journal of Cancer, 2006, 42, 310-318.	1.3	124

#	Article	IF	Citations
19	Tissue Inhibitor of Metalloproteinase (TIMP)-2 Acts Synergistically with Synthetic Matrix Metalloproteinase (MMP) Inhibitors but Not with TIMP-4 to Enhance the (Membrane Type) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf		
20	Tissue inhibitors of metalloproteinases (TEMP) in invasion and proliferation. Apmis, 1999, 107, 111-119.	0.9	111
21	Critical Role of STAT3 in IL-6â€“Mediated Drug Resistance in Human Neuroblastoma. Cancer Research, 2013, 73, 3852-3864.	0.4	109
22	Structure and Characterization of the Human Tissue Inhibitor of Metalloproteinases-2 Gene. Journal of Biological Chemistry, 1996, 271, 25498-25505.	1.6	103
23	Proteases and Protease Inhibitors in Tumor Progression. Advances in Experimental Medicine and Biology, 1997, 425, 89-97.	0.8	102
24	The Matrix Metalloproteinase Inhibitor Prinomastat Enhances Photodynamic Therapy Responsiveness in a Mouse Tumor Model. Cancer Research, 2004, 64, 2328-2332.	0.4	99
25	Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. Journal of Clinical Investigation, 2007, 117, 2702-2712.	3.9	94
26	Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. Cell Reports, 2018, 25, 2177-2191.e7.	2.9	92
27	The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer and Metastasis Reviews, 2019, 38, 483-492.	2.7	92
28	Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function. Journal of the National Cancer Institute, 2012, 104, 1470-1484.	3.0	86
29	Cooperation between Matrix Metalloproteinases and the Plasminogen Activator-Plasmin System in Tumor Progression. Enzyme & Protein, 1996, 49, 72-84.	1.6	84
30	INHIBITION OF MATRIX METALLOPROTEINASES THERAPEUTIC APPLICATIONS. Tissue Inhibitors of Matrix Metalloproteinases in Cancer. Annals of the New York Academy of Sciences, 1999, 878, 108-119.	1.8	81
31	A Galectin-3â€“Dependent Pathway Upregulates Interleukin-6 in the Microenvironment of Human Neuroblastoma. Cancer Research, 2012, 72, 2228-2238.	0.4	78
32	Mechanisms of invasion and metastasis in human neuroblastoma. Cancer and Metastasis Reviews, 2007, 25, 645-657.	2.7	77
33	A fatal case of inappropriate adh secretion induced by cyclophosphamide therapy. Cancer, 1979, 44, 896-898.	2.0	76
34	Cancer-Associated Fibroblasts: Understanding Their Heterogeneity. Cancers, 2020, 12, 3108.	1.7	76
35	Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer Cells. Cancer Research, 2005, 65, 1129-1135.	0.4	73
36	Identification of the Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Binding Site on the Hemopexin Carboxyl Domain of Human Gelatinase A by Site-directed Mutagenesis. Journal of Biological Chemistry, 1999, 274, 4421-4429.	1.6	69

#	Article	IF	Citations
37	Discoidin Domain Receptor 2 Mediates Tumor Cell Cycle Arrest Induced by Fibrillar Collagen. Journal of Biological Chemistry, 2005, 280, 40187-40194.	1.6	69
38	Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Letters, 2005, 228, 203-209.	3.2	66
39	Desmoplasia: A Response or a Niche?. Cancer Discovery, 2012, 2, 772-774.	7.7	66
40	Computerized Quantification of Tissue Vascularization Using High-resolution Slide Scanning of Whole Tumor Sections. Journal of Histochemistry and Cytochemistry, 2003, 51, 151-158.	1.3	64
41	More than the genes, the tumor microenvironment in neuroblastoma. Cancer Letters, 2016, 380, 304-314.	3.2	64
42	Matrix Metalloproteinases Play an Active Role in Wnt1-Induced Mammary Tumorigenesis. Cancer Research, 2006, 66, 2691-2699.	0.4	58
43	Identification of Galectin-3-binding Protein as a Factor Secreted by Tumor Cells That Stimulates Interleukin-6 Expression in the Bone Marrow Stroma. Journal of Biological Chemistry, 2008, 283, 18573-18581.	1.6	58
44	Bone Marrowâ€"Derived Mesenchymal Stromal Cells Promote Survival and Drug Resistance in Tumor Cells. Molecular Cancer Therapeutics, 2014, 13, 962-975.	1.9	58
45	Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. Clinical Cancer Research, 2019, 25, 4761-4774.	3.2	53
46	Bone Marrow Microenvironment and Tumor Progression. Cancer Microenvironment, 2008, 1, 23-35.	3.1	52
47	Contribution of neuroblastomaâ€derived exosomes to the production of proâ€tumorigenic signals by bone marrow mesenchymal stromal cells. Journal of Extracellular Vesicles, 2017, 6, 1332941.	5.5	47
48	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget, 2017, 8, 91516-91529.	0.8	45
49	NF-Y and Sp1 Cooperate for the Transcriptional Activation and cAMP Response of Human Tissue Inhibitor of Metalloproteinases-2. Journal of Biological Chemistry, 2000, 275, 18602-18610.	1.6	44
50	A phase I study of zoledronic acid and lowâ€dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study. Pediatric Blood and Cancer, 2011, 57, 275-282.	0.8	43
51	Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. Osteoporosis International, 2012, 23, 1399-1413.	1.3	43
52	The Activity of Zoledronic Acid on Neuroblastoma Bone Metastasis Involves Inhibition of Osteoclasts and Tumor Cell Survival and Proliferation. Cancer Research, 2007, 67, 9346-9355.	0.4	40
53	Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. Archives of Biochemistry and Biophysics, 1988, 265, 28-37.	1.4	38
54	Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. PLoS ONE, 2015, 10, e0133786.	1.1	38

#	Article	IF	Citations
55	Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Research, 2003, 63, 3026-31.	0.4	38
56	Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biology and Therapy, 2010, 10, 198-208.	1.5	37
57	The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives. Cancers, 2020, 12, 2912.	1.7	37
58	The Cyclin-dependent Kinase Inhibitors p15INK4B and p21CIP1 Are Critical Regulators of Fibrillar Collagen-induced Tumor Cell Cycle Arrest. Journal of Biological Chemistry, 2007, 282, 24471-24476.	1.6	35
59	Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma. Clinical Cancer Research, 2011, 17, 7093-7104.	3.2	34
60	Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. , 1996, 167, 333-340.		32
61	Urokinase induces receptor mediated brain tumor cell migration and invasion. Journal of Neuro-Oncology, 1998, 40, 215-226.	1.4	32
62	Primary central nervous system lymphoma without intracranial mass in a child diagnosis by documentation of monoclonality. Cancer, 1985, 56, 2804-2808.	2.0	30
63	Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. Life Sciences, 2011, 88, 693-700.	2.0	30
64	Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Therapy, 2003, 10, 435-444.	2.2	29
65	Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biology and Therapy, 2012, 13, 349-357.	1.5	28
66	TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. Experimental Cell Research, 2004, 293, 164-174.	1.2	27
67	Multimodal Imaging Analysis of Tumor Progression and Bone Resorption in a Murine Cancer Model. Journal of Computer Assisted Tomography, 2006, 30, 525-534.	0.5	27
68	Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biology and Therapy, 2012, 13, 534-541.	1.5	25
69	Establishment of Long-Termin VitroCultures of Human Ovarian Cystadenomas and LMP Tumors and Examination of Their Spectrum of Expression of Matrix-Degrading Proteinases. Gynecologic Oncology, 1997, 67, 277-284.	0.6	21
70	Magnetic resonance imaging for the evaluation of a novel metastatic orthotopic model of human neuroblastoma in immunodeficient mice. Clinical and Experimental Metastasis, 2000, 18, 455-461.	1.7	17
71	Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance. Molecular Cancer Therapeutics, 2017, 16, 2516-2527.	1.9	16
72	The C-Terminal Domain of Tissue Inhibitor of Metalloproteinases-2 Is Required for Cell Binding but Not for Antimetalloproteinase Activity. Biochemical and Biophysical Research Communications, 1997, 236, 100-105.	1.0	15

#	Article	IF	Citations
73	Hemophilus influenzae type b infections: Recurrent disease due to ampicillin-resistant strains. Journal of Pediatrics, 1977, 90, 319-320.	0.9	12
74	Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis. International Journal of Cancer, 2015, 137, 797-809.	2.3	12
75	Identification of the TIMP-2 Binding Site on the Gelatinase A Hemopexin C-Domain by Site-Directed Mutagenesis and the Yeast Two-Hybrid System. Annals of the New York Academy of Sciences, 1999, 878, 747-753.	1.8	9
76	MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. Cancer Research, 2014, 74, 5999-6009.	0.4	9
77	Macrocytosis and Pure RBC Anemia Caused by Azathioprine. JAMA Pediatrics, 1980, 134, 377.	3.6	8
78	Cloning and partial structure of the gene encoding human tissue inhibitor of metalloproteinases-3. Gene, 1996, 170, 287-288.	1.0	8
79	Les mÃ©talloprotÃ©ases matricielles et leurs inhibiteurs synthÃ©tiques dans la progression tumorale. Medecine/Sciences, 2002, 18, 565-575.	0.0	8
80	Paternal Risk Factors for Oral Clefts in Northern Africans, Southeast Asians, and Central Americans. International Journal of Environmental Research and Public Health, 2017, 14, 657.	1.2	8
81	Fat, Calories, and Cancer. Cancer Research, 2016, 76, 509-510.	0.4	5
82	Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy. Cancer Cell, 2005, 7, 408-409.	7.7	3
83	Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment. Journal of Visualized Experiments, 2017, , .	0.2	3
84	Focus on the cell membrane: The need for dissociation and detachment in tumoral invasion. Cancer Biology and Therapy, 2004, 3, 632-633.	1.5	0
85	17 Mesenchymal stem cells and the tumor microenvironment. , 2013, , 331-352.		0
86	The Extracellular Matrix and the Growth and Survival of Tumors. , 2010, , 695-710.		0
87	Tissue Inhibitors of Metalloproteinases in Cancer. , 2002, , 169-194.		0